09:23 AM EST, 01/06/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) said Monday it has received approval from the New York State Department of Health for its TissueCypher test, a tool designed to assess the risk of progression from Barrett's esophagus to esophageal cancer.

The company said the approval expands its New York Clinical Laboratory Permit to include this test, along with others in its dermatology, gastroenterology, and ophthalmology portfolios.

Shares of the company were up 4.2% in recent Monday premarket activity.